A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

PLoS Neglected Tropical Diseases

Volumn 11, Issue 5, 2017, Pages

  Osman, Mohamed ^a   Mistry, Anoop ^a   Keding, Ada ^a   Gabe, Rhian ^a   Cook, Elizabeth ^a   Forrester, Sarah ^a   Wiggins, Rebecca ^a   Di Marco, Stefania ^b   Colloca, Stefano ^b   Siani, Loredana ^b   Smith, Deborah F ^a   Aebischer, Toni ^c   Kaye, Paul M ^a   Lacey, Charles J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ReiThera Srl ^*  (Italy)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHAD63 KH; FANCONI ANEMIA GROUP A PROTEIN; GAMMA INTERFERON; HYDROCORTISONE; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 2; LEISHMANIA VACCINE; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DRUG CARRIER; PARASITE ANTIGEN; RECOMBINANT VACCINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; INJECTION SITE REACTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; PHASE 1 CLINICAL TRIAL; SKIN LEISHMANIASIS; TRANSCRIPTOMICS; UNSPECIFIED SIDE EFFECT; VACCINE IMMUNOGENICITY; VISCERAL LEISHMANIASIS; ADOLESCENT; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MIDDLE AGED; NORMAL HUMAN; SECRETION (PROCESS); SIMIAN VIRUS; YOUNG ADULT;

ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LEISHMANIA; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 85020440465     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005527     Document Type: Article

References (74)

1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS one. 2012;7(5):e35671. Epub 2012/06/14. PubMed Central PMCID: PMC3365071. doi: 10.1371/journal.pone.0035671 22693548
2. Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG, Case study for a vaccine against leishmaniasis. Vaccine. 2013;31Suppl 2:B244–9. Epub 2013/04/26.
3. Evans KJ, Kedzierski L, Development of Vaccines against Visceral Leishmaniasis. Journal of tropical medicine. 2012;2012:892817. Epub 2011/09/14. PubMed Central PMCID: PMC3170777. doi: 10.1155/2012/892817 21912561
4. Kaye PM, Aebischer T, Visceral leishmaniasis: immunology and prospects for a vaccine. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011;17(10):1462–70. Epub 2011/08/20.
5. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, et al. Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990–99. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2003;97(4):469–72. Epub 2004/07/21. 15259484
6. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. International journal of dermatology. 2002;41(2):73–8. Epub 2002/05/02. 11982640
7. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(1):58–63. Epub 2007/10/30. doi: 10.1016/j.trstmh.2007.08.006 17963805
8. Costa CH, Peters NC, Maruyama SR, de Brito EC, Jr.Santos IK, Vaccines for the leishmaniases: proposals for a research agenda. PLoS neglected tropical diseases. 2011;5(3):e943. Epub 2011/04/07. PubMed Central PMCID: PMC3066138. doi: 10.1371/journal.pntd.0000943 21468307
9. Dalton JE, Kaye PM, Immunomodulators: use in combined therapy against leishmaniasis. Expert review of anti-infective therapy. 2010;8(7):739–42. Epub 2010/07/01. doi: 10.1586/eri.10.64 20586558
10. Desjeux P, Ghosh RS, Dhalaria P, Strub-Wourgaft N, Zijlstra EE, Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27–29 June 2012. Parasites & vectors. 2013;6:196. Epub 2013/07/04. PubMed Central PMCID: PMC3733610.
11. Ghalib H, Modabber F, Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid biology and disease. 2007;6:7. Epub 2007/08/21. PubMed Central PMCID: PMC2000869. doi: 10.1186/1475-9292-6-7 17705861
12. Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, Losch FO, et al. Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. The Journal of infectious diseases. 2012;205(5):853–63. Epub 2012/02/04. PubMed Central PMCID: PMC3274377. doi: 10.1093/infdis/jir842 22301630
13. Musa AM, Noazin S, Khalil EA, Modabber F, Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2010;104(1):1–2. Epub 2009/08/29. doi: 10.1016/j.trstmh.2009.07.026 19712953
14. Engwerda CR, Matlashewski G, Development of Leishmania vaccines in the era of visceral leishmaniasis elimination. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2015;109(7):423–4. Epub 2015/06/07. doi: 10.1093/trstmh/trv039 26048873
15. Kaye P, Scott P, Leishmaniasis: complexity at the host-pathogen interface. Nature reviews Microbiology. 2011;9(8):604–15. Epub 2011/07/13. doi: 10.1038/nrmicro2608 21747391
16. Faleiro RJ, Kumar R, Bunn PT, Singh N, Chauhan SB, Sheel M, et al. Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. PLoS neglected tropical diseases. 2016;10(2):e0004415. Epub 2016/02/13. PubMed Central PMCID: PMC4752322. doi: 10.1371/journal.pntd.0004415 26872334
17. Gautam S, Kumar R, Singh N, Singh AK, Rai M, Sacks D, et al. CD8 T cell exhaustion in human visceral leishmaniasis. The Journal of infectious diseases. 2014;209(2):290–9. Epub 2013/08/08. PubMed Central PMCID: PMC3873784. doi: 10.1093/infdis/jit401 23922369
18. Joshi T, Rodriguez S, Perovic V, Cockburn IA, Stager S, B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS pathogens. 2009;5(5):e1000431. Epub 2009/05/14. PubMed Central PMCID: PMC2674929. doi: 10.1371/journal.ppat.1000431 19436710
19. Stager S, Joshi T, Bankoti R, Immune evasive mechanisms contributing to persistent Leishmania donovani infection. Immunologic research. 2010;47(1–3):14–24. Epub 2010/01/21. doi: 10.1007/s12026-009-8135-4 20087685
20. Stager S, Rafati S, CD8(+) T cells in leishmania infections: friends or foes?Frontiers in immunology. 2012;3:5. Epub 2012/05/09. PubMed Central PMCID: PMC3342007. doi: 10.3389/fimmu.2012.00005 22566891
21. Novais FO, Scott P, CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly. Seminars in immunopathology. 2015;37(3):251–9. Epub 2015/03/25. PubMed Central PMCID: PMC4439344. doi: 10.1007/s00281-015-0475-7 25800274
22. Polley R, Stager S, Prickett S, Maroof A, Zubairi S, Smith DF, et al. Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infection and immunity. 2006;74(1):773–6. Epub 2005/12/22. PubMed Central PMCID: PMC1346645. doi: 10.1128/IAI.74.1.773-776.2006 16369038
23. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, et al. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nature medicine. 2003;9(10):1287–92. Epub 2003/09/23. doi: 10.1038/nm933 14502281
24. Stager S, Smith DF, Kaye PM, Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol. 2000;165(12):7064–71. Epub 2000/12/20. 11120835
25. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S, Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol. 2005;174(11):7160–71. Epub 2005/05/21. 15905560
26. Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Science translational medicine. 2014;6(234):234ra56. Epub 2014/05/03. doi: 10.1126/scitranslmed.3008222 24786324
27. Gamboa-Leon R, Paraguai de Souza E, Borja-Cabrera GP, Santos FN, Myashiro LM, Pinheiro RO, et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine. 2006;24(22):4863–73. Epub 2006/04/26. doi: 10.1016/j.vaccine.2006.03.005 16635538
28. Grimaldi G, Jr.Teva A, Porrozzi R, Pinto MA, Marchevsky RS, Rocha MG, et al. Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen. PLoS neglected tropical diseases. 2014;8(6):e2853. Epub 2014/06/20. PubMed Central PMCID: PMC4063746. doi: 10.1371/journal.pntd.0002853 24945284
29. Ganguly S, Mukhopadhyay D, Das NK, Chaduvula M, Sadhu S, Chatterjee U, et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post-kala-azar dermal leishmaniasis. The Journal of investigative dermatology. 2010;130(4):1013–22. Epub 2009/12/25. doi: 10.1038/jid.2009.393 20032994
30. Mukherjee S, Mukhopadhyay D, Ghosh S, Barbhuiya JN, Das NK, Chatterjee M, Decreased Frequency and Secretion of CD26 Promotes Disease Progression in Indian Post Kala-azar Dermal Leishmaniasis. Journal of clinical immunology. 2016;36(1):85–94. Epub 2015/12/09. doi: 10.1007/s10875-015-0215-8 26644312
31. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009;27(35):4747–53. Epub 2009/06/23. doi: 10.1016/j.vaccine.2009.05.084 19540273
32. Duthie MS, Raman VS, Piazza FM, Reed SG, The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine. 2012;30(2):134–41. Epub 2011/11/17. PubMed Central PMCID: PMC3359766. doi: 10.1016/j.vaccine.2011.11.005 22085553
33. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. The Journal of infectious diseases. 2012;205(5):772–81. Epub 2012/01/26. PubMed Central PMCID: PMC3274376. doi: 10.1093/infdis/jir850 22275401
34. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PloS one. 2012;7(2):e31208. Epub 2012/03/01. PubMed Central PMCID: PMC3283618. doi: 10.1371/journal.pone.0031208 22363582
35. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular therapy: the journal of the American Society of Gene Therapy. 2012. Epub 2012/10/24.
36. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Molecular therapy: the journal of the American Society of Gene Therapy. 2011;19(12):2269–76. Epub 2011/08/25. PubMed Central PMCID: PMC3242658.
37. Antrobus RD, Coughlan L, Berthoud TK, Dicks MD, Hill AV, Lambe T, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Molecular therapy: the journal of the American Society of Gene Therapy. 2014;22(3):668–74. Epub 2014/01/01. PubMed Central PMCID: PMC3944330.
38. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. The Lancet infectious diseases. 2016;16(1):31–42. Epub 2015/11/08. doi: 10.1016/S1473-3099(15)00362-X 26546548
39. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nature methods. 2015;12(5):453–7. Epub 2015/03/31. PubMed Central PMCID: PMC4739640. doi: 10.1038/nmeth.3337 25822800
40. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Science translational medicine. 2012;4(115):115ra1. Epub 2012/01/06. doi: 10.1126/scitranslmed.3003155 22218690
41. De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. The Lancet infectious diseases. 2016;16(3):311–20. Epub 2016/01/05. doi: 10.1016/S1473-3099(15)00486-7 26725450
42. Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. The New England journal of medicine. 2016;374(17):1635–46. Epub 2015/01/30. doi: 10.1056/NEJMoa1411627 25629663
43. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine—Preliminary Report. The New England journal of medicine. 2015. Epub 2015/01/30.
44. Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. The Journal of clinical investigation. 2015;125(3):1129–46. Epub 2015/02/03. doi: 10.1172/JCI78280 25642773
45. Sobolev O, Binda E, O'Farrell S, Lorenc A, Pradines J, Huang Y, et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nature immunology. 2016;17(2):204–13. Epub 2016/01/05. doi: 10.1038/ni.3328 26726811
46. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(50):E3503–12. Epub 2012/11/16. PubMed Central PMCID: PMC3528489. doi: 10.1073/pnas.1208972109 23151505
47. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29(1):150–64. Epub 2008/07/18. PubMed Central PMCID: PMC2727981. doi: 10.1016/j.immuni.2008.05.012 18631455
48. Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nature immunology. 2014;15(2):195–204. Epub 2013/12/18. PubMed Central PMCID: PMC3946932. doi: 10.1038/ni.2789 24336226
49. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011;29(19):3531–7. Epub 2011/03/19. doi: 10.1016/j.vaccine.2011.02.096 21414377
50. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infection and immunity. 2007;75(9):4648–54. Epub 2007/07/04. PubMed Central PMCID: PMC1951162. doi: 10.1128/IAI.00394-07 17606603
51. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, Coler RN, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine. 2010;28(46):7427–35. Epub 2010/09/21. doi: 10.1016/j.vaccine.2010.08.092 20851080
52. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine. 2010;28(40):6581–7. Epub 2010/08/07. doi: 10.1016/j.vaccine.2010.07.063 20688040
53. Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, et al. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clinical & translational immunology. 2015;4(4):e35. Epub 2015/07/16. PubMed Central PMCID: PMC4488838.
54. Fletcher HA, Schrager L, TB vaccine development and the End TB Strategy: importance and current status. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(4):212–8. Epub 2016/04/15. PubMed Central PMCID: PMC4830404. doi: 10.1093/trstmh/trw016 27076508
55. Meyer J, Harris SA, Satti I, Poulton ID, Poyntz HC, Tanner R, et al. Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine. 2013;31(7):1026–33. Epub 2012/12/26. doi: 10.1016/j.vaccine.2012.12.042 23266342
56. Basu R, Bhaumik S, Haldar AK, Naskar K, De T, Dana SK, et al. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infection and immunity. 2007;75(12):5956–66. Epub 2007/10/03. PubMed Central PMCID: PMC2168357. doi: 10.1128/IAI.00944-07 17908806
57. Basu R, Roy S, Walden P, HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. The Journal of infectious diseases. 2007;195(9):1373–80. Epub 2007/04/03. doi: 10.1086/513439 17397010
58. Cardoso TM, Machado A, Costa DL, Carvalho LP, Queiroz A, Machado P, et al. Protective and Pathological Functions of CD8+ T Cells in Leishmania braziliensis Infection. Infection and immunity. 2015;83(3):898–906. Epub 2014/12/24. PubMed Central PMCID: PMC4333467. doi: 10.1128/IAI.02404-14 25534940
59. Warimwe GM, Gesharisha J, Carr BV, Otieno S, Otingah K, Wright D, et al. Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Scientific reports. 2016;6:20617. Epub 2016/02/06. PubMed Central PMCID: PMC4742904. doi: 10.1038/srep20617 26847478
60. Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, von Gegerfelt A, et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine. 2011;29(39):6742–54. Epub 2011/01/05. PubMed Central PMCID: PMC3115438. doi: 10.1016/j.vaccine.2010.12.056 21195080
61. de Felipe P, Martin V, Cortes ML, Ryan M, Izquierdo M, Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene therapy. 1999;6(2):198–208. Epub 1999/08/06. doi: 10.1038/sj.gt.3300811 10435104
62. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(7):917–24. Epub 2011/02/02. PubMed Central PMCID: PMC3068063.
63. Mir FA, Kaufmann SH, Eddine AN, A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire. Clinical and vaccine immunology: CVI. 2009;16(10):1467–75. Epub 2009/08/07. PubMed Central PMCID: PMC2756856. doi: 10.1128/CVI.00237-09 19656992
64. Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ open. 2015;5(10):e008748. Epub 2015/10/30. PubMed Central PMCID: PMC4636663. doi: 10.1136/bmjopen-2015-008748 26510727
65. Boyd A, Almeida JR, Darrah PA, Sauce D, Seder RA, Appay V, et al. Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection. PloS one. 2015;10(6):e0128714. Epub 2015/06/06. PubMed Central PMCID: PMC4457486. doi: 10.1371/journal.pone.0128714 26046523
66. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature medicine. 2007;13(7):843–50. Epub 2007/06/15. doi: 10.1038/nm1592 17558415
67. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nature medicine. 2013;19(10):1305–12. Epub 2013/09/24. doi: 10.1038/nm.3350 24056771
68. Haining WN, Pulendran B, Identifying gnostic predictors of the vaccine response. Current opinion in immunology. 2012;24(3):332–6. Epub 2012/05/29. PubMed Central PMCID: PMC3383371. doi: 10.1016/j.coi.2012.03.010 22633886
69. Nakaya HI, Pulendran B, Systems vaccinology: its promise and challenge for HIV vaccine development. Current opinion in HIV and AIDS. 2012;7(1):24–31. Epub 2011/12/14. PubMed Central PMCID: PMC3253345. doi: 10.1097/COH.0b013e32834dc37b 22156839
70. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology. 2009;10(1):116–25. Epub 2008/11/26. doi: 10.1038/ni.1688 19029902
71. Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, et al. Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines. 2016;4(3). Epub 2016/08/05. PubMed Central PMCID: PMC5041021.
72. Zijlstra EE, The immunology of post-kala-azar dermal leishmaniasis (PKDL). Parasites & vectors. 2016;9:464. Epub 2016/08/25. PubMed Central PMCID: PMC4995613.
73. Borducchi EN, Cabral C, Stephenson KE, Liu J, Abbink P, Ng'ang'a D, et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature. 2016;540(7632):284–7. Epub 2016/11/15. PubMed Central PMCID: PMC5145754. doi: 10.1038/nature20583 27841870
74. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB, The economic value of a visceral leishmaniasis vaccine in Bihar state, India. The American journal of tropical medicine and hygiene. 2012;86(3):417–25. Epub 2012/03/10. PubMed Central PMCID: PMC3284356. doi: 10.4269/ajtmh.2012.10-0415 22403311